Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
Add more filters










Publication year range
1.
Braz J Med Biol Res ; 54(6): e10754, 2021.
Article in English | MEDLINE | ID: mdl-33886813

ABSTRACT

Epidermal growth factor receptor (EGFR) signaling and components of the fibrinolytic system, including urokinase-type plasminogen activator (uPA) and thrombomodulin (TM), have been implicated in tumor progression. In the present study, we employed cBioPortal platform (http://www.cbioportal.org/), cancer cell lines, and an in vivo model of immunocompromised mice to evaluate a possible cooperation between EGFR signaling, uPA, and TM expression/function in the context of cervical cancer. cBioPortal analysis revealed that EGFR, uPA, and TM are positively correlated in tumor samples of cervical cancer patients, showing a negative prognostic impact. Aggressive human cervical cancer cells (CASKI) presented higher gene expression levels of EGFR, uPA, and TM compared to its less aggressive counterpart (C-33A cells). EGFR induces uPA expression in CASKI cells through both PI3K-Akt and MEK1/2-ERK1/2 downstream effectors, whereas TM expression induced by EGFR was dependent on PI3K/Akt signaling alone. uPA induced cell-morphology modifications and cell migration in an EGFR-dependent and -independent manner, respectively. Finally, treatment with cetuximab reduced in vivo CASKI xenografted-tumor growth in nude mice, and decreased intratumoral uPA expression, while TM expression was unaltered. In conclusion, we showed that EGFR signaling regulated expression of the fibrinolytic system component uPA in both in vitro and in vivo settings, while uPA also participated in cell-morphology modifications and migration in a human cervical cancer model.


Subject(s)
Phosphatidylinositol 3-Kinases , Uterine Cervical Neoplasms , Animals , Cell Line, Tumor , Cell Movement , ErbB Receptors , Female , Humans , Mice , Mice, Nude , Prognosis , Uterine Cervical Neoplasms/drug therapy
2.
Braz. j. med. biol. res ; 54(6): e10754, 2021. tab, graf
Article in English | LILACS | ID: biblio-1285670

ABSTRACT

Epidermal growth factor receptor (EGFR) signaling and components of the fibrinolytic system, including urokinase-type plasminogen activator (uPA) and thrombomodulin (TM), have been implicated in tumor progression. In the present study, we employed cBioPortal platform (http://www.cbioportal.org/), cancer cell lines, and an in vivo model of immunocompromised mice to evaluate a possible cooperation between EGFR signaling, uPA, and TM expression/function in the context of cervical cancer. cBioPortal analysis revealed that EGFR, uPA, and TM are positively correlated in tumor samples of cervical cancer patients, showing a negative prognostic impact. Aggressive human cervical cancer cells (CASKI) presented higher gene expression levels of EGFR, uPA, and TM compared to its less aggressive counterpart (C-33A cells). EGFR induces uPA expression in CASKI cells through both PI3K-Akt and MEK1/2-ERK1/2 downstream effectors, whereas TM expression induced by EGFR was dependent on PI3K/Akt signaling alone. uPA induced cell-morphology modifications and cell migration in an EGFR-dependent and -independent manner, respectively. Finally, treatment with cetuximab reduced in vivo CASKI xenografted-tumor growth in nude mice, and decreased intratumoral uPA expression, while TM expression was unaltered. In conclusion, we showed that EGFR signaling regulated expression of the fibrinolytic system component uPA in both in vitro and in vivo settings, while uPA also participated in cell-morphology modifications and migration in a human cervical cancer model.


Subject(s)
Humans , Animals , Female , Rats , Uterine Cervical Neoplasms/drug therapy , Phosphatidylinositol 3-Kinases , Prognosis , Cell Movement , Cell Line, Tumor , ErbB Receptors , Mice, Nude
3.
Biomol NMR Assign ; 11(2): 293-296, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28856584

ABSTRACT

Ixolaris is a two-Kunitz tick salivary gland protein identified in Ixodes scapularis that presents sequence homology to TFPI (tissue factor pathway inhibitor). It binds to the coagulation enzyme factor Xa (FXa) or to its zymogen form, FX, and further inhibits tissue factor/FVIIa complex (extrinsic Xnase compex). Differently from TFPI, Ixolaris does not bind to the active site cleft of FXa. Instead, complex formation is mediated by the FXa heparin-binding exosite, which may also results in decreased FXa activity into the prothrombinase complex. The Ixolaris-FXa/FX complex formation has been characterized by using a combination of biophysical and biochemical technics although no structural data is currently available. In this study, we reported the NMR chemical shift assignment of Ixolaris, as a first step to further establishing the structure, dynamics and function relationship for this protein.


Subject(s)
Nuclear Magnetic Resonance, Biomolecular , Salivary Glands/metabolism , Salivary Proteins and Peptides/chemistry , Salivary Proteins and Peptides/metabolism , Ticks , Animals , Protein Structure, Secondary
4.
Protein Expr Purif ; 139: 49-56, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28734839

ABSTRACT

Ixolaris is an anticoagulant protein identified in the tick saliva of Ixodes scapularis. Ixolaris contains 2 Kunitz like domains and binds to Factor Xa or Factor X as a scaffold for inhibition of the Tissue Factor (TF)/Factor VIIa (FVIIa). In contrast to tissue factor pathway inhibitor (TFPI), however, Ixolaris does not bind to the active site cleft of FXa. Instead, complex formation is mediated by the FXa heparin-binding exosite. Due to its potent and long-lasting antithrombotic activity, Ixolaris is a promising agent for anticoagulant therapy. Although numerous functional studies of Ixolaris exist, three-dimensional structure of Ixolaris has not been obtained at atomic resolution. Using the pET32 vector, we successfully expressed a TRX-His6-Ixolaris fusion protein. By combining Ni-NTA chromatography, enterokinase protease cleavage, and reverse phase HPLC (RP-HPLC), we purified isotopically labeled Ixolaris for NMR studies. 1D 1H and 2D 15N-1H NMR analysis yielded high quality 2D 15N-1H HSQC spectra revealing that the recombinant protein is folded. These studies represent the first steps in obtaining high-resolution structural information by NMR for Ixolaris enabling the investigation of the molecular basis for Ixolaris-coagulation factors interactions.


Subject(s)
Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Salivary Glands/chemistry , Salivary Proteins and Peptides/chemistry , Salivary Proteins and Peptides/genetics , Anticoagulants/chemistry , Anticoagulants/metabolism , Cloning, Molecular , Escherichia coli/genetics , Histidine/genetics , Nuclear Magnetic Resonance, Biomolecular , Oligopeptides/genetics , Recombinant Fusion Proteins/metabolism , Salivary Proteins and Peptides/metabolism
5.
J Mol Biol ; 425(22): 4479-95, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-23938203

ABSTRACT

Human ß-defensins (hBDs) are believed to function as alarm molecules that stimulate the adaptive immune system when a threat is present. In addition to its antimicrobial activity, defensins present other activities such as chemoattraction of a range of different cell types to the sites of inflammation. We have solved the structure of the hBD6 by NMR spectroscopy that contains a conserved ß-defensin domain followed by an extended C-terminus. We use NMR to monitor the interaction of hBD6 with microvesicles shed by breast cancer cell lines and with peptides derived from the extracellular domain of CC chemokine receptor 2 (Nt-CCR2) possessing or not possessing sulfation on Tyr26 and Tyr28. The NMR-derived model of the hBD6/CCR2 complex reveals a contiguous binding surface on hBD6, which comprises amino acid residues of the α-helix and ß2-ß3 loop. The microvesicle binding surface partially overlaps with the chemokine receptor interface. NMR spin relaxation suggests that free hBD6 and the hBD6/CCR2 complex exhibit microsecond-to-millisecond conformational dynamics encompassing the CCR2 binding site, which might facilitate selection of the molecular configuration optimal for binding. These data offer new insights into the structure-function relation of the hBD6-CCR2 interaction, which is a promising target for the design of novel anticancer agents.


Subject(s)
Receptors, CCR2/chemistry , beta-Defensins/chemistry , Amino Acid Sequence , Binding Sites , Breast Neoplasms/metabolism , Cell Line, Tumor , Cytoplasmic Vesicles/chemistry , Cytoplasmic Vesicles/metabolism , Female , Humans , Models, Molecular , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Sequence Data , Multiprotein Complexes/chemistry , Nuclear Magnetic Resonance, Biomolecular , Protein Binding , Protein Conformation , Protein Multimerization , Receptors, CCR2/metabolism , beta-Defensins/metabolism
6.
J Thromb Haemost ; 10(9): 1849-58, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22823596

ABSTRACT

BACKGROUND: Tissue factor (TF) is frequently overexpressed in cancer cells and correlated with more aggressive tumor phenotypes and poor prognosis. In addition to promoting coagulation-dependent metastasis and cancer-associated thrombosis, tumor cell-expressed TF mediates direct cell signaling involving the protease-activated receptor (PAR) 2. Ixolaris is a tick-derived inhibitor of the TF-factor (F)VIIa-Xa coagulation initiation complex which blocks primary tumor growth and angiogenesis in glioblastoma and melanoma models. METHODS: In this study we address the anti-tumor effects of Ixolaris in TF-VIIa-PAR2 signaling-dependent breast cancer models, a xenograft model of highly aggressive human MDA-MB-231 mfp cells and a syngeneic model of PAR2-deficient and replete PyMT mouse mammary carcinoma cells. RESULTS: Ixolaris potently inhibited the procoagulant activity of human MDA-MB-231mfp or murine PyMT breast cancer cells. Ixolaris blocked signaling by the ternary TF-FVIIa-FXa complex, and, surprisingly, at higher concentrations also the binary TF-FVIIa complex on MDA-MB-231 cells. We show that Ixolaris interacts with certain residues in the human VIIa protease domain that are involved in PAR2 cleavage. In contrast to human VIIa, Ixolaris was a poor inhibitor of murine TF-FVIIa signaling and did not attenuate PAR2-dependent tumor growth in a syngeneic mouse model of breast cancer progression. CONCLUSION: These data show that Ixolaris inhibits PAR2 cleavage specifically by human TF signaling complexes and suggest that Ixolaris may block tumor growth of human cell models with ectopic FVIIa expression through inhibition of direct TF-FVIIa-PAR2 signaling as well as its anticoagulant activity.


Subject(s)
Salivary Proteins and Peptides/physiology , Signal Transduction/physiology , Thromboplastin/metabolism , Animals , Cell Line, Tumor , Factor VIIa/metabolism , Humans , Mice , Models, Molecular
7.
Braz J Med Biol Res ; 43(4): 403-8, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20445954

ABSTRACT

A correlation between cancer and hypercoagulability has been described for more than a century. Patients with cancer are at increased risk for thrombotic complications and the clotting initiator protein, tissue factor (TF), is possibly involved in this process. Moreover, TF may promote angiogenesis and tumor growth. In addition to TF, thrombin seems to play a relevant role in tumor biology, mainly through activation of protease-activated receptor-1 (PAR-1). In the present study, we prospectively studied 39 lung adenocarcinoma patients in relation to the tumor expression levels of TF and PAR-1 and their correlation with thrombosis outcome and survival. Immunohistochemical analysis showed TF positivity in 22 patients (56%), most of them in advanced stages (III and IV). Expression of PAR-1 was found in 15 patients (39%), most of them also in advanced stages (III and IV). Remarkably, no correlation was observed between the expression of TF or PAR-1 and risk for thrombosis development. On the other hand, patients who were positive for TF or PAR-1 tended to have decreased long-term survival. We conclude that immunolocalization of either TF or PAR-1 in lung adenocarcinoma may predict a poor prognosis although lacking correlation with thrombosis outcome.


Subject(s)
Adenocarcinoma/complications , Lung Neoplasms/complications , Receptor, PAR-1/metabolism , Thromboplastin/metabolism , Thrombosis/etiology , Adenocarcinoma/metabolism , Aged , Aged, 80 and over , Female , Humans , Immunohistochemistry , Lung Neoplasms/metabolism , Male , Middle Aged , Neoplasm Seeding , Prognosis , Prospective Studies , Receptor, PAR-1/analysis , Thromboplastin/analysis , Thrombosis/metabolism
8.
Braz. j. med. biol. res ; 43(4): 403-408, Apr. 2010. ilus, tab, graf
Article in English | LILACS | ID: lil-543572

ABSTRACT

A correlation between cancer and hypercoagulability has been described for more than a century. Patients with cancer are at increased risk for thrombotic complications and the clotting initiator protein, tissue factor (TF), is possibly involved in this process. Moreover, TF may promote angiogenesis and tumor growth. In addition to TF, thrombin seems to play a relevant role in tumor biology, mainly through activation of protease-activated receptor-1 (PAR-1). In the present study, we prospectively studied 39 lung adenocarcinoma patients in relation to the tumor expression levels of TF and PAR-1 and their correlation with thrombosis outcome and survival. Immunohistochemical analysis showed TF positivity in 22 patients (56 percent), most of them in advanced stages (III and IV). Expression of PAR-1 was found in 15 patients (39 percent), most of them also in advanced stages (III and IV). Remarkably, no correlation was observed between the expression of TF or PAR-1 and risk for thrombosis development. On the other hand, patients who were positive for TF or PAR-1 tended to have decreased long-term survival. We conclude that immunolocalization of either TF or PAR-1 in lung adenocarcinoma may predict a poor prognosis although lacking correlation with thrombosis outcome.


Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Adenocarcinoma/complications , Lung Neoplasms/complications , Receptor, PAR-1/metabolism , Thromboplastin/metabolism , Thrombosis/etiology , Adenocarcinoma/metabolism , Immunohistochemistry , Lung Neoplasms/metabolism , Neoplasm Seeding , Prognosis , Prospective Studies , Receptor, PAR-1/analysis , Thromboplastin/analysis , Thrombosis/metabolism
9.
J Thromb Haemost ; 7(11): 1855-64, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19624457

ABSTRACT

BACKGROUND: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. OBJECTIVES: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. METHODS AND RESULTS: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. CONCLUSION: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.


Subject(s)
Cell Proliferation/drug effects , Glioblastoma/drug therapy , Neovascularization, Pathologic/drug therapy , Salivary Proteins and Peptides/pharmacology , Thromboplastin/antagonists & inhibitors , Animals , Cell Line, Tumor , Disease Progression , Down-Regulation/drug effects , Glioblastoma/pathology , Humans , Mice , Mice, Nude , Salivary Proteins and Peptides/therapeutic use , Vascular Endothelial Growth Factor A/genetics
10.
Braz J Med Biol Res ; 41(2): 99-105, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18235964

ABSTRACT

A correlation between cancer and prothrombotic states has long been described. More recently, a number of studies have focused on the procoagulant mechanisms exhibited by tumor cells. In the present study, we dissected the molecular mechanisms responsible for the procoagulant activity of MV3, a highly aggressive human melanoma cell line. It was observed that tumor cells strongly accelerate plasma coagulation as a result of: i) expression of the blood clotting initiator protein, a tissue factor, as shown by flow cytometry and functional assays (factor Xa formation in the presence of cells and factor VIIa), and ii) direct activation of prothrombin to thrombin by cells, as evidenced by hydrolysis of the synthetic substrate, S-2238, and the natural substrate, fibrinogen. This ability was highly potentiated by the addition of exogenous factor Va, which functions as a co-factor for the enzyme factor Xa. In contrast, prothrombin activation was not observed when cells were previously incubated with DEGR-factor Xa, an inactive derivative of the enzyme. Moreover, a monoclonal antibody against bovine factor Xa reduced the prothrombin-converting activity of tumor cells. In conclusion, the data strongly suggest that MV3 cells recruit factor Xa from the culture medium, triggering an uncommon procoagulant mechanism.


Subject(s)
Cysteine Endopeptidases/physiology , Melanoma/metabolism , Neoplasm Proteins/physiology , Prothrombin/metabolism , Thrombin/metabolism , Thromboplastin/metabolism , Cell Line, Tumor/chemistry , Cysteine Endopeptidases/drug effects , Factor V/pharmacology , Factor VIIa/pharmacology , Factor Xa/pharmacology , Flow Cytometry , Humans , Melanoma/chemistry , Neoplasm Proteins/drug effects
11.
Braz. j. med. biol. res ; 41(2): 99-105, Feb. 2008. graf
Article in English | LILACS | ID: lil-474760

ABSTRACT

A correlation between cancer and prothrombotic states has long been described. More recently, a number of studies have focused on the procoagulant mechanisms exhibited by tumor cells. In the present study, we dissected the molecular mechanisms responsible for the procoagulant activity of MV3, a highly aggressive human melanoma cell line. It was observed that tumor cells strongly accelerate plasma coagulation as a result of: i) expression of the blood clotting initiator protein, a tissue factor, as shown by flow cytometry and functional assays (factor Xa formation in the presence of cells and factor VIIa), and ii) direct activation of prothrombin to thrombin by cells, as evidenced by hydrolysis of the synthetic substrate, S-2238, and the natural substrate, fibrinogen. This ability was highly potentiated by the addition of exogenous factor Va, which functions as a co-factor for the enzyme factor Xa. In contrast, prothrombin activation was not observed when cells were previously incubated with DEGR-factor Xa, an inactive derivative of the enzyme. Moreover, a monoclonal antibody against bovine factor Xa reduced the prothrombin-converting activity of tumor cells. In conclusion, the data strongly suggest that MV3 cells recruit factor Xa from the culture medium, triggering an uncommon procoagulant mechanism.


Subject(s)
Humans , Cysteine Endopeptidases/physiology , Melanoma/metabolism , Neoplasm Proteins/physiology , Prothrombin/metabolism , Thrombin/metabolism , Thromboplastin/metabolism , Cell Line, Tumor/chemistry , Cysteine Endopeptidases/drug effects , Flow Cytometry , Factor V/pharmacology , Factor VIIa/pharmacology , Factor Xa/pharmacology , Melanoma/chemistry , Neoplasm Proteins/drug effects
12.
J Thromb Haemost ; 5(1): 155-65, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17002660

ABSTRACT

BACKGROUND: Plasmodium falciparum malaria infects 300-500 million people every year, causing 1-2 million deaths annually. Evidence of a coagulation disorder, activation of endothelial cells (EC) and increase in inflammatory cytokines are often present in malaria. OBJECTIVES: We have asked whether interaction of parasitized red blood cells (pRBC) with EC induces tissue factor (TF) expression in vitro and in vivo. The role of phosphatidylserine-containing pRBC to support the assembly of blood coagulation complexes was also investigated. RESULTS: We demonstrate that mature forms of pRBC induce functional expression of TF by EC in vitro with productive assembly of the extrinsic Xnase complex and initiation of the coagulation cascade. Late-stage pRBC also support the prothrombinase and intrinsic Xnase complex formation in vitro, and may function as activated platelets in the amplification phase of the blood coagulation. Notably, post-mortem brain sections obtained from P. falciparum-infected children who died from cerebral malaria and other causes display a consistent staining for TF in the EC. CONCLUSIONS: These findings place TF expression by endothelium and the amplification of the coagulation cascade by pRBC and/or activated platelets as potentially critical steps in the pathogenesis of malaria. Furthermore, it may allow investigators to test other therapeutic alternatives targeting TF or modulators of EC function in the treatment of malaria and/or its complications.


Subject(s)
Blood Coagulation , Endothelial Cells/metabolism , Erythrocytes/metabolism , Erythrocytes/parasitology , Malaria, Cerebral/blood , Plasmodium falciparum/isolation & purification , Thromboplastin/metabolism , Adolescent , Animals , Brain/blood supply , Brain/parasitology , Brain/pathology , Brain Chemistry , Cells, Cultured , Child , Child, Preschool , Endothelial Cells/chemistry , Endothelial Cells/parasitology , Endothelial Cells/pathology , Factor V/metabolism , Factor Xa/metabolism , Female , Humans , Immunohistochemistry , Infant , Malaria, Cerebral/metabolism , Malaria, Cerebral/parasitology , Malaria, Cerebral/pathology , Male , Microcirculation/cytology , Microcirculation/metabolism , Middle Aged , Severity of Illness Index , Thromboplastin/analysis , Time Factors
13.
J Thromb Haemost ; 4(7): 1546-52, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16839352

ABSTRACT

BACKGROUND: That there is a correlation between cancer and procoagulant states is well-known. C6 glioma cell line was originally induced in random-bred Wistar-Furth rats and is morphologically similar to glioblastoma multiforme, the most common aggressive glioma resistant to therapeutic interventions. OBJECTIVES: In this study we analyzed the molecular mechanisms responsible for the highly procoagulant properties of C6 glioma cells. METHODS: The presence of tissue factor (TF) and phosphatidylserine (PS) in C6 cells was investigated by flow-cytometric and functional analyses. The assembly of extrinsic tenase, intrinsic tenase and prothrombinase complexes on these cells was studied using enzymatic assays employing plasma or purified proteins. RESULTS: TF was identified by flow-cytometric and functional [factor (F) Xa formation in the presence of cells and FVIIa] assays. Alternatively, conversion of FX into FXa was also observed in the presence of C6 cells, FIXa and FVIIIa. This effect was both cell- and FVIIIa-dependent, being consistent with formation of the intrinsic tenase complex. C6 cells were also able to activate prothrombin in the presence of FXa and FVa, thus supporting formation of the prothrombinase complex. This ability was similar to positive controls performed with PS-containing vesicles. Accordingly, exposure of PS on C6 cells was demonstrated by flow cytometry employing specific anti-PS antibodies. In addition, annexin V, which blocks PS binding sites, inhibited FX and prothrombin conversion by their respective C6-assembled activating complexes. CONCLUSION: C6 glioma cells support all procoagulant reactions leading to robust thrombin formation. This ability results from concomitant TF exposure and from the presence of the anionic lipid PS at the outer leaflet of cell membrane. Therefore, this animal cell line may be used to explore new aspects concerning the role of blood coagulation proteins in tumor biology, especially those affecting the central nervous system.


Subject(s)
Blood Coagulation , Glioma/pathology , Animals , Blood Coagulation Factors/metabolism , Cell Line, Tumor , Cysteine Endopeptidases/metabolism , Flow Cytometry , Glioma/chemistry , Glioma/physiopathology , Humans , Neoplasm Proteins/metabolism , Phosphatidylserines/analysis , Rats , Thrombin/biosynthesis , Thromboplastin/analysis , Thromboplastin/metabolism
14.
Protein Sci ; 10(9): 1897-904, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11514680

ABSTRACT

Bothrojaracin (BJC) is a 27-kD snake venom protein from Bothrops jararaca that has been characterized as a potent thrombin inhibitor. BJC binds to exosites I and II, with a dissociation constant of 0.7 nM, and influences but does not block the proteinase catalytic site. BJC also binds prothrombin through an interaction that has not been characterized. In the present work we characterize the interaction of BJC with prothrombin quantitatively for the first time, and identify the BJC binding site on human prothrombin. Gel filtration chromatography demonstrated calcium-independent, 1:1 complex formation between fluorescein-labeled BJC ([5F]BJC) and prothrombin, whereas no interactions were observed with activation fragments 1 or 2 of prothrombin. Isothermal titration calorimetry showed that binding of BJC to prothrombin is endothermic, with a dissociation constant of 76 +/- 32 nM. The exosite I-specific ligand, hirudin(54-65) (Hir(54-65) (SO(3)(-)), displaced competitively [5F]BJC from prothrombin. Titration of the fluorescent hirudin(54-65) derivative, [5F]Hir(54-65)(SO(3)(-)), with human prothrombin showed a dissociation constant of 7.0 +/- 0.2 microM, indicating a approximately 100-fold lower binding affinity than that exhibited by BJC. Both ligands, however, displayed a similar, approximately 100-fold increase in affinity for exosite I when prothrombin was activated to thrombin. BJC efficiently displaced [5F]Hir(54-65)(SO(3)(-)) from complexes formed with thrombin or prothrombin with dissociation constants of 0.7 +/- 0.9 nM and 11 +/- 80 nM, respectively, indicating that BJC and Hir(54-65)(SO(3)(-)) compete for the same exosite on these molecules. The results indicate that BJC is a potent and specific probe of the partially exposed anion-binding exosite (proexosite I) of human prothrombin.


Subject(s)
Bothrops , Crotalid Venoms/chemistry , Crotalid Venoms/metabolism , Prothrombin/chemistry , Prothrombin/metabolism , Animals , Binding, Competitive , Calorimetry , Chromatography, Gel , Fluorescence Polarization , Humans , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding , Thermodynamics , Thrombin/antagonists & inhibitors , Thrombin/metabolism
15.
Toxicon ; 39(6): 787-92, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11137537

ABSTRACT

Many of the components of Bothrops jararaca venom are proteolytic enzymes. In the present work, we investigated the proteolytic action of B. jararaca venom upon its own constituents. Crude venom was reconstituted and incubated at pH 5.0 or 8.5 for up to 48h at room temperature. Aliquots taken at 0, 24 and 48h of incubation were then tested for proteolytic activity and several biological activities, as well as electrophoretic migration pattern and antibody recognition. Rate of hydrolysis of azocasein by venom samples was not changed by the incubation, but hemagglutinating activity decreased by 93% after 24h of incubation at pH 8.5, with no detectable changes at pH 5.0. Incubation of venom samples caused a progressive increase in phospholipase A(2) and procoagulant activities that was more evident in samples incubated at pH 5.0. The electrophoretic migration pattern showed no significant change for venom samples incubated at pH 5.0, whereas in samples incubated at pH 8.5 bands in the region between 66 and 45kDa gradually disappeared. The addition of a mixture of protease inhibitors (EDTA, PMSF, PPACK and benzamidine) effectively protected against venom degradation at pH 8.5. The cocktail of inhibitors also reduced the changes in phospholipase A(2) activity found in venom samples incubated at pH 5.0. Recognition of venom samples by polyclonal antibodies raised against crude venom was progressively lost during incubation at both pH 5.0 and 8.5; again the addition of protease inhibitors protected against loss of antibody recognition. We conclude that prolonged manipulation of B. jararaca venom at an acidic or alkaline pH can produce significant changes in its biological properties.


Subject(s)
Blood Proteins/metabolism , Bothrops , Crotalid Venoms/pharmacology , Animals , Crotalid Venoms/metabolism , Electrophoresis, Polyacrylamide Gel , Humans , Hydrogen-Ion Concentration , Hydrolysis , Kinetics , Phospholipases A/metabolism
16.
Haemostasis ; 31(3-6): 273-8, 2001.
Article in English | MEDLINE | ID: mdl-11910195

ABSTRACT

Bothrojaracin (BJC) is a 27-kD protein from Bothrops jararaca venom that interacts with alpha-thrombin (K(D) = 0.7 nM) through both anion-binding exosites I and II. Recently, it has been shown that BJC interacts with the exosite I precursor (proexosite I) on human prothrombin (K(D) = 75 nM), forming a 1:1 Ca(2+)-independent noncovalent complex with the zymogen. Complex formation was associated with inhibition of zymogen activation by Oxyuranus scutellatus venom. In addition, BJC strongly decreased the prothrombin activation by factor Xa only in the presence of factor Va. A similar effect was observed in the presence of phospholipids, suggesting that BJC specifically inhibits the interaction of prothrombin with factor Va. It is proposed that BJC has two independent mechanisms for anticoagulation: (1) inhibition of exosite-I-dependent activities on alpha-thrombin, and (2) inhibition of prothrombin activation through interaction with proexosite I.


Subject(s)
Crotalid Venoms/pharmacokinetics , Prothrombin/metabolism , Animals , Anticoagulants/metabolism , Anticoagulants/pharmacokinetics , Anticoagulants/pharmacology , Binding Sites , Crotalid Venoms/metabolism , Crotalid Venoms/pharmacology , Drug Interactions , Humans , Thrombin/antagonists & inhibitors
17.
Arch Biochem Biophys ; 382(1): 123-8, 2000 Oct 01.
Article in English | MEDLINE | ID: mdl-11051105

ABSTRACT

Bothrojaracin is a potent and specific alpha-thrombin inhibitor (Kd approximately 0.6 nM) isolated from Bothrops jararaca venom. It binds to both of thrombin's anion-binding exosites (1 and 2), thus inhibiting the ability of the enzyme to act upon several natural macromolecular substrates, such as fibrinogen, platelet receptor, protein C, and factor V. Additionally, bothrojaracin interacts with prothrombin (Kd approximately 30 nM), as previously determined by a solid-phase assay. However, there is no information concerning the effect of this interaction on prothrombin activation and whether the binding of bothrojaracin can occur in plasma. Here, we show that bothrojaracin specifically interacts with prothrombin in human plasma. It is an effective anticoagulant after activation of the intrinsic pathway of blood coagulation, and analysis of prothrombin conversion in plasma shows that bothrojaracin strongly reduces alpha-thrombin formation. To determine whether this effect is due exclusively to inhibition of feedback reactions involving the thrombin-induced activation of factors V and VIII, we analyzed the effect of bothrojaracin on the activation of purified prothrombin by Oxyuranus scutellatus venom. As with plasma, bothrojaracin greatly inhibited thrombin formation, suggesting a direct interference in the prothrombin activation by the enzyme found in this venom (scuterin, a prothrombin activator described as a factor Xa/factor Va-like complex). Altogether, we suggest that bothrojaracin exerts its anticoagulant effect in plasma by two distinct mechanisms: (1) it binds generated thrombin and inhibits exosite 1 dependent activities such as fibrinogen clotting and factor V activation, and (2) it interacts with prothrombin and decreases its proteolytic activation. Thus, bothrojaracin may be useful in the search for thrombin inhibitors that bind both the zymogen and the active enzyme.


Subject(s)
Crotalid Venoms/chemistry , Crotalid Venoms/pharmacology , Lectins/pharmacology , Prothrombin/antagonists & inhibitors , Prothrombin/metabolism , Animals , Anions , Anticoagulants/pharmacology , Binding Sites , Blotting, Western , Bothrops , Elapid Venoms/chemistry , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Factor V/metabolism , Fibrinogen/metabolism , Humans , Kinetics , Plasma/metabolism , Protein Binding , Thrombin/biosynthesis , Time Factors
18.
Biochem Biophys Res Commun ; 262(3): 819-22, 1999 Sep 07.
Article in English | MEDLINE | ID: mdl-10471408

ABSTRACT

Bothrojaracin, a 27-kDa C-type lectin from Bothrops jararaca venom, is a selective and potent thrombin inhibitor (K(d) = 0.6 nM) which interacts with the two thrombin anion-binding exosites (I and II) but not with its catalytic site. In the present study, we analyzed the allosteric effects produced in the catalytic site by bothrojaracin binding to thrombin exosites. Opposite effects were observed with alpha-thrombin, which possesses both exosites I and II, and with gamma-thrombin, which lacks exosite I. On the one hand, bothrojaracin altered both kinetic parameters K(m) and k(cat) of alpha-thrombin for small synthetic substrates, resulting in an increased efficiency of alpha-thrombin catalytic activity. This effect was similar to that produced by hirugen, a peptide based on the C-terminal hirudin sequence (residues 54-65) which interacts exclusively with exosite I. On the other hand, bothrojaracin decreased the amidolytic activity of gamma-thrombin toward chromogenic substrates, although this effect was observed with higher concentrations of bothrojaracin than those used with alpha-thrombin. In agreement with these observaions, bothrojaracin produced opposite effects on the fluorescence intensity of alpha- and gamma-thrombin derivatives labeled at the active site with fluorescein-Phe-Pro-Arg-chloromethylketone. These observations support the conclusion that bothrojaracin binding to thrombin produces two different structural changes in its active site, depending on whether it interacts exclusively with exosite II, as seen with gamma-thrombin, or with exosite I (or both I and II) as observed with alpha-thrombin. The ability of bothrojaracin to evoke distinct modifications in the thrombin catalytic site environment when interacting with exosites I and II make this molecule an interesting tool for the study of allosteric changes in the thrombin molecule.


Subject(s)
Crotalid Venoms/pharmacology , Thrombin/chemistry , Thrombin/metabolism , Allosteric Regulation , Allosteric Site , Antithrombins/pharmacology , Binding Sites , Catalytic Domain , Fibrinogen/metabolism , Hirudins/analogs & derivatives , Hirudins/pharmacology , Humans , Kinetics , Peptide Fragments/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Substrate Specificity , Thrombin/antagonists & inhibitors
19.
Article in English | MEDLINE | ID: mdl-9854824

ABSTRACT

More than one isoform of bothrojaracin (BJC), a potent and specific thrombin inhibitor isolated from Bothrops jararaca venom, has been found in individual venoms collected from adult snakes. Variations in snake venom composition have previously been associated with factors such as age, sex, geographic origin, season of the year and diet. In order to obtain further information concerning individual patterns of expression of BJC isoforms, we have analyzed five individual Bothrops jararaca snake venoms collected at the same time from adult female snakes from the same geographic region. As expected, crude venoms showed a similar migration pattern on SDS-PAGE. BJC was purified using a procedure which includes an affinity chromatography step (PPACK-thrombin Sepharose). A slight variation in the amount of BJC obtained from individual venom samples was noticed. Inhibition of thrombin-induced platelet aggregation as well as migration pattern on SDS-PAGE (under reducing and non-reducing conditions) and isoelectric focusing varied considerably among BJC samples from the five snakes. The amino-terminal sequences (residues 1-34) of individual BJC samples were compared with the sequence deduced from isolated cDNAs encoding alpha and beta chains of BJC. A high degree of homology was detected, although some residues differed from one sample to other. Altogether, data confirmed the heterogeneity found for BJC purified from individual snakes. Thus, the results indicate that: (1) individual specimens of Bothrops jararaca have different patterns of BJC isoform expression; and (2) it seems that genetic factors, at least in part, determine the variability found in BJC production.


Subject(s)
Bothrops/metabolism , Crotalid Venoms/chemistry , Amino Acid Sequence , Amino Acids/analysis , Animals , Bothrops/genetics , Chromatography, Affinity , Chromatography, Gel , Crotalid Venoms/biosynthesis , Crotalid Venoms/genetics , DNA, Complementary/genetics , Electrophoresis, Polyacrylamide Gel , Female , Genetic Variation , In Vitro Techniques , Molecular Sequence Data , Platelet Aggregation Inhibitors/chemistry , Platelet Aggregation Inhibitors/metabolism , Rabbits , Sequence Homology, Amino Acid , Thrombin/antagonists & inhibitors
20.
Toxicon ; 36(1): 153-63, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9604289

ABSTRACT

Bothrojaracin (BJC) is a potent thrombin inhibitor isolated from the venom of Bothrops jararaca. Venoms from individual snakes have been shown to vary in BJC content, and more than one molecular variant (isoform) has been identified in the same venom. In order to determine whether the production of this protein and its isoforms varies under seasonally invariant conditions, an analysis was made of BJC isolated from venoms collected individually once a month for 10 months from two female B. jararaca snakes kept under conditions of constant temperature and photoperiod. The crude venom from each individual snake exhibited a characteristic pattern of protein bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), with no noticeable variation throughout the collecting period. BJC from individual venoms was purified by gel filtration on Sephacryl S-200 followed by an affinity column (PPACK-thrombin Sepharose). BJC content and other activities such as phospholipase A2, azocaseinolytic activity and inhibition of thrombin-induced platelet aggregation varied considerably among the samples. Purified BJC from both snakes inhibited fibrin coagulation and migrated as a single band of 27,000 mol. wt on SDS-PAGE. However, the BJC pattern on non-denaturing PAGE differed between the two snakes, with four to six bands per sample each month, which were all recognized by polyclonal anti-BJC antibodies. The isoelectric focusing pattern of BJC was also characteristic for each snake, with only minor differences throughout the collecting period. These results indicate that under seasonally invariant conditions: (1) there was a considerable variation over the 10-month period in the production of BJC and other important venom activities such as phospholipase A2 and proteinases; (2) individual B. jararaca snakes produced a distinctive array of BJC isoforms; and (3) despite quantitative differences, there were essentially no qualitative differences in the production of BJC isoforms by individual snakes during the 10-month period.


Subject(s)
Bothrops , Crotalid Venoms/analysis , Crotalid Venoms/chemistry , Platelet Aggregation Inhibitors/analysis , Seasons , Thrombin/antagonists & inhibitors , Animals , Electrophoresis, Polyacrylamide Gel , Female , Isoelectric Focusing , Phospholipases A/antagonists & inhibitors , Phospholipases A2 , Rabbits
SELECTION OF CITATIONS
SEARCH DETAIL
...